All
Afinitor Impresses in Advanced Breast Cancer
Afinitor (exemestane) and an aromatase inhibitor delay cancer growth in metastatic breast cancer.
Novel Hormone Therapy Combination Shown to Prolong Survival
A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.
Zometa’s Survival Benefit Confirmed
Women receiving a supportive care drug to reduce bone loss caused by breast cancer treatment may actually be getting more than that—improved survival and lower risk of metastatic recurrence.
An update on the Cancer Genome Atlas for breast cancer
Video blog: Test could spare some DCIS patients from radiation
Video blog: HER2-targeted agents
Video blog: Complications with brachytherapy in breast cancer
Video blog: CLEOPATRA and pertuzumab in breast cancer
Video blog: BOLERO-2 and Afinitor in breast cancer
Afinitor impresses in advanced hormone-positive breast cancers
Fertility takes center stage at SABCS
Preventing late recurrences – New insights from San Antonio
Blogroll for San Antonio's breast cancer meeting
Breast Cancer and the Environment Report offers research roadmap
Saving your oocytes
Arriving at the San Antonio Breast Cancer Symposium
What to look for at this year's SABCS breast cancer meeting
Understanding the new affordable health care act
Aspirin delivers on colorectal cancer prevention
Women and lung cancer: Time to turn the tide
The Emperor of All Maladies: A Biography of Cancer
The environment and cancer
Learning to be a caregiver
Pink power moms unite
A very special corgi
Drug approved specifically for treating myelofibrosis
The Great American Smokeout
I'm not dead yet!
Cancer Coach on your mobile phone
Who walks for you
